GRTS Gritstone Bio Inc

EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today...

-- Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction...

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. ( Gritstone or the Company ) (NASDAQ: GRTS). Such investors are...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. ( Gritstone or the Company ) (NASDAQ: GRTS). Such investors are...

-- Preliminary data from Phase 2 portion of Phase 2/3 study evaluating GRANITE, Gritstone's personalized cancer vaccine in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC...